Annals of the Rheumatic Diseases
Fecha de publicación: July 6, 2018
Autores: Lianne Kearsley-Fleet, Rebecca Davies, Diederik De Cock, Kath D Watson, Mark Lunt, Maya H Buch, John D Isaacs, Kimme L Hyrich.
Background: Biologic disease-modifying antirheumatic drugs (bDMARDs) have revolutionised treatment and outcomes for rheumatoid arthritis (RA). The expanding repertoire allows the option of switching bDMARD if current treatment is not effective. For some patients, even after switching, disease control remains elusive. This analysis aims to quantify the frequency of, and identify factors associated with, bDMARD refractory disease.